Trial · NCT03010176
Adverse events845
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 845
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 14 | 32 | 17 |
| other | Anaemia | Blood and lymphatic system disorders | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 27 | 66 | 42 |
| other | Anaemia | Blood and lymphatic system disorders | Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions) | 6 | 26 | 11 |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory | 11 | 21 | 14 |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC | 7 | 25 | 9 |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 2 | 32 | 2 |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 1 | 66 | 1 |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions) | 1 | 26 | 1 |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory | 0 | 21 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC | 0 | 25 | 0 |
| other | Lymph node pain | Blood and lymphatic system disorders | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 2 | 32 | 3 |
| other | Lymph node pain | Blood and lymphatic system disorders | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 1 | 66 | 1 |
| other | Lymph node pain | Blood and lymphatic system disorders | Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions) | 0 | 26 | 0 |
| other | Lymph node pain | Blood and lymphatic system disorders | Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory | 1 | 21 | 2 |
| other | Lymph node pain | Blood and lymphatic system disorders | Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC | 0 | 25 | 0 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 2 | 32 | 2 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 1 | 66 | 1 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions) | 0 | 26 | 0 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory | 0 | 21 | 0 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC | 0 | 25 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03010176/events